Three different approaches to the same destination. Injectable NAD+ bypasses conversion. NMN and NR are oral precursors with different evidence bases. Here's how to choose.
Research context only. This page is for educational purposes based on published research. Not medical advice.
NAD+, NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside) all ultimately raise NAD+ levels in cells — but through different routes, with different bioavailability profiles, different costs, and different clinical evidence bases.
| Injectable NAD+ | NMN (oral) | NR (oral) | |
|---|---|---|---|
| What it is | The final coenzyme | Direct NAD+ precursor | NAD+ precursor (2-step) |
| Conversion needed? | No — direct delivery | 1 enzymatic step | 2 enzymatic steps |
| Bioavailability | High (bypasses gut) | Moderate (oral) | Moderate (oral) |
| Speed of action | Fast — hours | Slower — days | Slower — days |
| Human trial data | Moderate | Strong (Washington U) | Strong (multiple RCTs) |
| Cost | Highest | Moderate | Lowest |
| Convenience | Injection required | Oral capsule | Oral capsule |
| Flush risk | IV only (SubQ avoids) | None | None |
The NAD+ biosynthesis pathway runs: Tryptophan → NR → NMN → NAD+. Each step requires a specific enzyme. Injectable NAD+ jumps to the end of this chain — it's the final product delivered directly.
NMN requires one enzymatic conversion (NMNAT) to become NAD+. Research from Washington University showed that oral NMN raises blood NMN levels and muscle NAD+ in older adults. The conversion enzyme is present in most tissues.
NR requires two enzymatic steps. It has the most completed human RCTs of the three. Studies show it raises blood NAD+ metabolites and has cardiovascular and metabolic benefits in several populations.
The conversion efficiency question: Whether 500mg of oral NMN translates to the same intracellular NAD+ elevation as 500mg of injectable NAD+ is unknown — the conversion efficiency varies by tissue, age, and individual enzyme expression. Injectable NAD+ removes this variable entirely.
NR has the most completed human clinical trials — it's been studied in heart failure, muscle aging, Parkinson's disease, and healthy aging populations. NMN has strong mechanistic backing and growing clinical data. Injectable NAD+ has the fastest delivery kinetics but fewer large-scale RCTs in its injectable form specifically.
The honest assessment: for people who want the highest-quality oral option, NR or NMN have the strongest published RCT evidence. For people who want maximum bioavailability and rapid NAD+ repletion, injectable bypasses all the uncertainty of oral conversion. Both approaches are legitimate.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator